HS
DNTH icon

HighVista Strategies’s Dianthus Therapeutics DNTH Stock Holding History

HighVista Strategies’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.99M Sell
35,587
-12,897
-27% -$747K 0.82% 37
2025
Q4 		$2M Sell
48,484
-5,741
-11% -$223K 0.51% 52
2025
Q3 		$2.13M Buy
54,225
+38,364
+242% +$980K 0.52% 58
2025
Q2 		$295K Sell
15,861
-15,526
-49% -$291K 0.11% 138
2025
Q1 		$569K Hold
31,387
– – 0.22% 121
2024
Q4 		$684K Buy
31,387
+11,579
+58% +$298K 0.25% 116
2024
Q3 		$542K Buy
+19,808
New +$552K 0.19% 124

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HighVista Strategies's DNTH Position: Q1 2026 in Review

HighVista Strategies reduced its Dianthus Therapeutics (DNTH) stake by 27% in Q1 2026, selling an estimated $747K and leaving 35,587 shares worth $2.99M. The position accounts for 0.82% of the portfolio, ranked #37.

HighVista Strategies first reported a position in DNTH in Q3 2024 and has held it in 7 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • HighVista Strategies held 35,587 shares of Dianthus Therapeutics worth $2.99M as of Q1 2026.
  • HighVista Strategies sold 12,897 Dianthus Therapeutics shares in Q1 2026, an estimated $747K.
  • Dianthus Therapeutics made up 0.82% of HighVista Strategies's portfolio in Q1 2026, its #37 holding.
  • HighVista Strategies first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.